LifeVantage Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2014. Although the request identifies “2013 Q4,” this filing is the annual report for FY2014; it also reports fourth-quarter results.
Business context
LifeVantage sells dietary supplements and skin-care products primarily through independent distributors and preferred customers in the U.S., Japan, Hong Kong, Australia, Canada, the Philippines and Mexico. Protandim remains its principal product. The company launched its LifeVantage TrueScience skin-care line in April 2014 and acquired sports-nutrition products for further research before launch.
Financial results and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $214.0 million | $208.2 million |
| Gross profit / margin | $180.8 million / 84.5% | $171.5 million / 82.4% |
| Operating income / margin | $19.4 million / 9.1% | $12.1 million / 5.8% |
| Net income / diluted EPS | $11.4 million / $0.10 | $7.6 million / $0.06 |
| Cash from operations | $12.1 million | $10.7 million |
- Revenue grew 2.8%. Management attributed the increase mainly to Americas growth and the TrueScience launch; foreign exchange reduced reported revenue by approximately $10.4 million.
- Fourth-quarter revenue was $56.0 million versus $51.5 million a year earlier; net income was $2.4 million versus a net loss of $0.2 million.
- At year-end, cash was $20.4 million, working capital was $17.3 million, total assets were $54.0 million and total liabilities were $50.0 million. Debt principal was approximately $30.8 million, including $4.7 million current and $26.1 million long-term principal.
- Operating cash flow was $12.1 million; investing cash use was $2.2 million and financing cash use was $15.8 million. Financing cash use included $46.2 million of share repurchases and $16.2 million of term-loan principal payments, partly offset by loan proceeds.
- The company reported compliance with its credit-facility covenants at June 30, 2014. Management said cash and operating cash flow should cover requirements for at least 12 months.
Changes, outlook and material risks
- Americas revenue increased 6.1%; Asia/Pacific revenue declined 3.2% as reported. Japan revenue declined 11.0% in U.S. dollars, though local-currency revenue increased 3.2%; yen weakness reduced Japan revenue by about $9.7 million.
- Active independent distributors rose 1.5% to approximately 68,000, while active preferred customers fell 7.2% to approximately 128,000.
- Gross margin recovered from FY2013, which included $4.8 million in product-recall costs. Management expects gross margin of approximately 84–85%; it expects moderate revenue growth, but provided no specific revenue or earnings guidance.
- Management cited Japan distributor discord and regulatory scrutiny, foreign-exchange exposure, reliance on Protandim, distributor retention, product acceptance, supply-chain and IT execution, and direct-selling and product-claim regulation as significant risks.
- The company completed a tender offer for approximately 16.3 million shares at $2.45 per share and other repurchases; total FY2014 repurchases were approximately 19.6 million shares for $46.2 million. It authorized a further $4 million program for FY2015.
- Two lawsuits include claims seeking more than $20 million each, one against the company and one counterclaim against it. Management stated it considers the claims without merit and believes pending litigation is unlikely to have a material impact.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls; management also reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Whether the TrueScience launch and any later products offset Protandim concentration and the decline in preferred customers.
- Japan distributor trends, local-currency sales, yen exposure and the effects of the 20% Japan price increase implemented in April 2014.
- Debt repayment capacity and covenant headroom, especially given the substantial repurchases and $20.4 million year-end cash balance.
- Progress and potential outcomes in the disclosed litigation, and any changes in regulatory scrutiny or product-claim compliance.
- Potential dilution: the filing reports approximately 4.2 million warrants and 5.1 million options outstanding at year-end.